TBI is a major cause of death and disability in the United States; DRG Epidemiology estimates that there were 250,000 moderate to severe TBI events diagnosed in U.S. hospitals / emergency rooms in…
Clarivate Epidemiology’s coverage of hospital treated (HT) gram-negative infections (GNIs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…
The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy antihistamines, prescribed for both chronic inducible and chronic spontaneous…
Payers play a significant role in determining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential…
DRG Epidemiology’s coverage of peripheral arterial disease (PAD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of PAD for…
Biosimilars referencing Roche/Genentech’s portfolio of blockbuster oncology monoclonal antibodies—Avastin, Herceptin, and Rituxan—launched in the United States throughout the second half of…
The treatment of neuropathic pain involves the use of drugs from several drug classes, including antidepressants, antiepileptic drugs, local anesthetics, dual-acting opioid analgesics, and opioid…
Beta thalassemia is a rare genetic blood disorder characterized by a substantial reduction in or lack of beta-globin protein, resulting in chronic anemia, failure to thrive, jaundice, pallor, poor…
Despite the number of therapy options available, advanced or metastatic HR-positive / HER2-negative breast cancer remains incurable and a major cause of mortality and morbidity in women. Later-line…
The type 2 diabetes (T2D) drug market is expected to expand, fueled by a rich pipeline of agents. However, growth will be tempered because these emerging therapies will be predominantly later-to-…
Insomnia is a highly prevalent condition with obvious indirect economic costs, but payers may not be fully aware of the healthcare cost savings that could result from ensuring patient access to…
Oncology Clinical Trial Monitor is a continuously updated dashboard, highlighting the global immuno-oncology clinical development landscape and clinical outcomes for key standards of care. This…
Oncology Clinical Trial Monitor is a continuously updated dashboard, highlighting the global immuno-oncology clinical development landscape and clinical outcomes for key standards of care. This…
OA pain is the second largest segment of the overall chronic pain market, affecting more than 90 million patients in the G7. The OA pain market represents a lucrative opportunity for drug…
Drug treatment of chronic heart failure (CHF) with reduced ejection fraction (HFrEF) is well established with a wealth of supporting evidence from clinical trials. ACE inhibitors or ARBs, beta…